Skip to main content

IMvigor130 trial

Participants of the phase III IMvigor130 clinical trial – all of whom have untreated locally advanced or metastatic urothelial carcinoma (mUC) – are randomly assigned to receive the PD-L1 inhibitor atezolizumab, either alone or alongside platinum-based chemotherapy, with chemotherapy alone being the comparator arm.

Data on the co-primary endpoint of progression-free survival (PFS) were reported at the ESMO 2019 Congress. Adding atezolizumab to chemotherapy significantly prolongs PFS in the first-line advanced urothelial cancer setting

Enrique Grande tells us why the IMvigor130 data, although very promising, are not quite ready for translation to the clinic yet (1:43):

Read the transcript

Receive all the latest conference coverage straight to your inbox

Back to the WCLC 2019 conference hub